Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications
- PMID: 32959403
- DOI: 10.1002/med.21732
Mitochondrial dysfunction in cardiovascular disease: Current status of translational research/clinical and therapeutic implications
Abstract
Mitochondria provide energy to the cell during aerobic respiration by supplying ~95% of the adenosine triphosphate (ATP) molecules via oxidative phosphorylation. These organelles have various other functions, all carried out by numerous proteins, with the majority of them being encoded by nuclear DNA (nDNA). Mitochondria occupy ~1/3 of the volume of myocardial cells in adults, and function at levels of high-efficiency to promptly meet the energy requirements of the myocardial contractile units. Mitochondria have their own DNA (mtDNA), which contains 37 genes and is maternally inherited. Over the last several years, a variety of functions of these organelles have been discovered and this has led to a growing interest in their involvement in various diseases, including cardiovascular (CV) diseases. Mitochondrial dysfunction relates to the status where mitochondria cannot meet the demands of a cell for ATP and there is an enhanced formation of reactive-oxygen species. This dysfunction may occur as a result of mtDNA and/or nDNA mutations, but also as a response to aging and various disease and environmental stresses, leading to the development of cardiomyopathies and other CV diseases. Designing mitochondria-targeted therapeutic strategies aiming to maintain or restore mitochondrial function has been a great challenge as a result of variable responses according to the etiology of the disorder. There have been several preclinical data on such therapies, but clinical studies are scarce. A major challenge relates to the techniques needed to eclectically deliver the therapeutic agents to cardiac tissues and to damaged mitochondria for successful clinical outcomes. All these issues and progress made over the last several years are herein reviewed.
Keywords: arrhythmias; atherosclerosis; cardiomyopathy; cardiovascular disease; heart failure; hypertension; mitochondria; mitochondrial DNA; mitochondrial dysfunction.
© 2020 Wiley Periodicals LLC.
Similar articles
-
Significance of Mitochondria DNA Mutations in Diseases.Adv Exp Med Biol. 2017;1038:219-230. doi: 10.1007/978-981-10-6674-0_15. Adv Exp Med Biol. 2017. PMID: 29178079 Review.
-
Mitochondrial Dysfunction and Cardiovascular Disease: Pathophysiology and Emerging Therapies.Oxid Med Cell Longev. 2022 Aug 2;2022:9530007. doi: 10.1155/2022/9530007. eCollection 2022. Oxid Med Cell Longev. 2022. Retraction in: Oxid Med Cell Longev. 2024 Jan 9;2024:9785792. doi: 10.1155/2024/9785792. PMID: 35958017 Free PMC article. Retracted. Review.
-
Mitochondrial Dysfunction in Cardiovascular Diseases.Int J Mol Sci. 2025 Feb 23;26(5):1917. doi: 10.3390/ijms26051917. Int J Mol Sci. 2025. PMID: 40076543 Free PMC article. Review.
-
The mitochondrial genome in human adaptive radiation and disease: on the road to therapeutics and performance enhancement.Gene. 2005 Jul 18;354:169-80. doi: 10.1016/j.gene.2005.05.001. Gene. 2005. PMID: 16024186 Review.
-
Mitochondrial Genome Variants as a Cause of Mitochondrial Cardiomyopathy.Cells. 2022 Sep 11;11(18):2835. doi: 10.3390/cells11182835. Cells. 2022. PMID: 36139411 Free PMC article. Review.
Cited by
-
Mitochondrial transplantation as a novel therapeutic strategy for cardiovascular diseases.J Transl Med. 2023 May 25;21(1):347. doi: 10.1186/s12967-023-04203-6. J Transl Med. 2023. PMID: 37231493 Free PMC article. Review.
-
Sea buckthorn flavonoids and their derivatives: potential natural compounds for the treatment of diabetic cardiomyopathy.Front Pharmacol. 2025 Jul 17;16:1599756. doi: 10.3389/fphar.2025.1599756. eCollection 2025. Front Pharmacol. 2025. PMID: 40746722 Free PMC article. Review.
-
SBK3 suppresses angiotensin II-induced cardiac hypertrophy by regulating mitochondrial metabolism.Sci Rep. 2025 Jul 2;15(1):22796. doi: 10.1038/s41598-025-05584-y. Sci Rep. 2025. PMID: 40594551 Free PMC article.
-
Is Intrinsic Cardioprotection a Laboratory Phenomenon or a Clinically Relevant Tool to Salvage the Failing Heart?Int J Mol Sci. 2023 Nov 18;24(22):16497. doi: 10.3390/ijms242216497. Int J Mol Sci. 2023. PMID: 38003687 Free PMC article. Review.
-
The Role of mTOR in Doxorubicin-Altered Cardiac Metabolism: A Promising Therapeutic Target of Natural Compounds.Cardiovasc Toxicol. 2024 Feb;24(2):146-157. doi: 10.1007/s12012-023-09820-7. Epub 2023 Dec 18. Cardiovasc Toxicol. 2024. PMID: 38108960 Review.
References
REFERENCES
-
- Pecoraro M, Pinto A, Popolo A. Mitochondria and cardiovascular disease: a brief account. Crit Rev Eukaryot Gene Expr. 2019;29:295-304.
-
- Yu E, Mercer J, Bennett M. Mitochondria in vascular disease. Cardiovasc Res. 2012;95:173-182.
-
- Nguyen BY, Ruiz-Velasco A, Bui T, Collins L, Wang X, Liu W. Mitochondrial function in the heart: the insight into mechanisms and therapeutic potentials. Br J Pharmacol. 2019;176:4302-4318.
-
- Tian R, Colucci WS, Arany Z, et al. Unlocking the secrets of mitochondria in the cardiovascular system. Circulation. 2019;140:1205-1216.
-
- Brown DA, Perry JB, Allen ME, et al. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2017;14:238-250.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources